MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says results from probe into ArtemiC product show it is effective in preventing increased production of cytokine. MGC says cytokine storms are "believed to be the main reason for mortality in severe Covid-19 patients". "The findings from the phase II clinical trials which are supported by the completed preclinical trial results, continue to demonstrate the effectiveness of ArtemiC in treating patients with different variants of Covid-19," MGC Managing Director Roby Zomer says.
Current stock price: 3.67 pence
Year-to-date change: up 54% since February 9
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.